Bayer recalls one lot of cancer drug Vitrakvi in US over microbial contamination
Customers who have the recalled lot should immediately stop use of the drug and contact their physician or healthcare provider, the company said.;
United States: Bayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi in the U.S. due to the presence of microbial contamination that was observed during routine stability testing.
The company has not received any adverse event reports related to the lot to date, it said.
The drug, Vitrakvi, is approved for use in patients who have advanced solid tumor cancers with a rare gene mutation.
Bayer identified Penicillium brevicompactum, a type of slow-growing fungus, as the source of the contamination.
It said there was a "reasonable probability" that ingestion of the fungus in patients using the drug may result in invasive fungal infections of the blood or life-threatening pneumonia since they are already immunocompromised.
A company spokesperson said the recalled lot comprised of 192 100ml glass bottles of the oral solution form of the drug.
Read also: Bayer gets USFDA nod to FoundationOne CDx as Companion Diagnostic for larotrectinib
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.